News

Early Menopause Tied to Increased CVD Risk


 

From the annual meeting of the Endocrine Society

Major Finding: Women who had menopause before age 46 were 2.1 times more likely to have a CVD event later in life, compared with those who had menopause later.

Data Source: A cohort analysis of 2,509 women in MESA followed for an average of 7 years.

Disclosures: The study was funded by the National Heart, Lung, and Blood Institute.

SAN DIEGO — Women who go through menopause before age 46 are twice as likely to have a heart attack, stroke, or other cardiovascular event later in life as are women who do not go through early menopause, results from a large, multiethnic study showed.

“Our study is observational, so we cannot conclude that early menopause somehow causes these cardiovascular disease events, but our findings support using early menopause as a marker of increased cardiovascular disease risk,” Dr. Melissa F. Wellons said during a press briefing at the meeting.

“Getting clinicians to ask women about menopause and about when they went through menopause is an important part of potentially determining what their risk of CVD is in the future. Doing that can give them information on placing these women with early menopause into a higher-risk group and counseling them appropriately, such as encouraging them to stop smoking, exercise, and lose weight.”

Dr. Wellons, a fellow in the department of medicine at the University of Alabama at Birmingham, and her associates evaluated data from 2,509 women enrolled in the observational Multi-Ethnic Study of Atherosclerosis (MESA), funded by the National Institutes of Health. It included more than 6,000 women, from six communities in the United States, who were recruited in 2000 and followed for an average of 7 years. Most (40%) were white, 25% were black, 22% were Hispanic, and 13% were Chinese American.

“Our work is important because previous studies that have found a relationship between early menopause and cardiovascular disease events have taken place in primarily European and white cohorts,” Dr. Wellons noted.

The researchers defined early menopause as occurring before age 46, either naturally or surgically through removal of both ovaries, and they tracked the incidence of CVD among all study participants. At baseline, the women ranged in age from 45 to 84 years. Of the 2,509 women, 693 (28%) reported early menopause. Of these, 446 (64%) had natural menopause and 247 (36%) had surgical menopause.

In the early menopause group, 41 women (5.9%) had CVD events during the study period. Among those who did not have early menopause, 47 women (2.6%) had CVD events. The difference was significant.

After adjusting for race/ethnicity, level of education, smoking history, hypertension, total cholesterol, HDL cholesterol, diabetes, and whether the menopause was natural or surgical, the investigators found that women in the early menopause group were 2.1 times more likely to experience a CVD event than were women who didn't have early menopause. Further adjustment for current or previous use of hormone therapy and body mass index produced identical results.

“The risk of having a heart attack, stroke, or other cardiovascular disease event later in life doubles in women with early menopause,” Dr. Wellons concluded. “We found [this] in a large, U.S., multiethnic cohort, so our findings are generalizable to the U.S. population.”

'We found [this risk] in a large, U.S., multiethnic cohort, so our findings are generalizable.'

Source DR. WELLONS

Recommended Reading

Drug Combo Approved for Advanced Breast Ca
MDedge Endocrinology
Some PCOS Therapies Cut Cardiovascular Risk : Data on cardiometabolic risk in PCOS treatment show cyproterone acetate to be a 'bad actor.'
MDedge Endocrinology
Removal of Ovaries Raises Heart, Osteoporosis, Cancer Risk
MDedge Endocrinology
Pregnancy After Breast Ca May Be Protective
MDedge Endocrinology
Coffee May Cut Endometrial Ca Risk
MDedge Endocrinology
Specific Fats in Diet Tied to Endometriosis Risk
MDedge Endocrinology
Adolescent Obesity Linked to Midlife Nulliparity
MDedge Endocrinology
Side Effects Similar in Both DMPA Formulations
MDedge Endocrinology
FDA Panel Backs New Emergency Contraceptive
MDedge Endocrinology
Panel: Hypoactive Sexual Desire Disorder Drug Ineffective
MDedge Endocrinology